Lipocortin 1 (LC1) is an important mediator of glucocorticoid action in the anterior pituitary gland, where it appears to act via cell surface binding sites to suppress peptide release. We have exploited a combination of fluorescence-activated cell (FAC) analysis/sorting and electron microscopy to detect, characterize, and localize LC1-binding sites on the surface of dispersed rat anterior pituitary cells, using human recombinant LC1 (hu-r-LC1) as a probe. High affinity (K d ϭ 14 Ϯ 3 nM) hu-r-LC1-binding sites were detected on approximately 80% of anterior pituitary cells dispersed with collagenase. The binding characteristics of the ligand resembled those observed in leukocytes, in that it was saturable; concentration, Ca 2ϩ , and temperature dependent; and abolished by trypsin. Functional studies demonstrated an excellent correlation between the presence of the cell surface binding protein and the capacity of an anti-LC1 monoclonal antibody to abrogate the inhibitory actions of dexamethasone (10 nM) on the release of ACTH initiated in vitro by CRH-41 (1 nM). Morphological analysis of cells harvested by FAC sorting showed that 1) somatotrophs, corticotrophs, lactotrophs, thyrotrophs, and gonadotrophs were all included in the population expressing LC1 binding sites; and 2) the LC1-binding sites assume a punctate distribution across the cell surface. These data show that anterior pituitary cells express high affinity surface LC1-binding protein(s); they thus provide further evidence for a specific membrane mechanism of action of LC1 in regulating the endocrine function of the anterior pituitary. (Endocrinology 138: 5341-5351, 1997) L IPOCORTIN 1 (LC1; also called annexin 1) is a 37-kDa member of the annexin superfamily of Ca 2ϩ -and phospholipid-binding proteins (1-3). Since its initial identification in extracts of conditioned medium from glucocorticoid-stimulated peritoneal macrophages (4), LC1 has been shown to exhibit a wide range of glucocorticoid-like activities and has been widely advocated as a mediator of these steroids, particularly in immune/inflammatory cells (2, 3) and the neuroendocrine system (2, 5). Our recent in vivo and in vitro studies have identified a significant role for LC1 in effecting the negative feedback action of the glucocorticoids in the hypothalamo-pituitary-adrenal axis at the levels of both the hypothalamus (5-7) and the anterior pituitary gland (5, 8). Further studies have shown that LC1 also contributes to the less well documented inhibitory actions of the glucocorticoids on the release of PRL (9), GH (10), and TSH (11). LC1 is expressed in abundance in the anterior pituitary gland where, as in several peripheral cell types (12, 13), both its synthesis and subcellular distribution are under glucocorticoid control (8, 14) . Exposure of anterior pituitary tissue to glucocorticoids in vivo or in vitro thus increases the cellular turnover of LC1 causing 1) rapid exportation of the protein from intracellular stores to the outer surface of the cell membrane where it is retained by a Ca 2ϩ -dependent mechanism and 2) de novo synthesis of the protein to replenish the depleted tissue stores (15, 16) . Several lines of evidence from our functional studies suggest that the prompt exportation of LC1 from cells is critical because it enables the protein to gain access to cell surface binding sites and thereby to exert its biological actions. Firstly, on a temporal basis, exportation of the protein parallels manifestation of the steroid-induced inhibition of ACTH release (8). Secondly, processes that inhibit the cellular exportation of LC1 (protein synthesis inhibitors and LC1 antisense oligonucleotides) also abolish the inhibitory actions of glucocorticoids on the secretion of ACTH, GH, PRL, 16) . Thirdly, the regulatory actions of the steroids on pituitary hormone release in vivo and in vitro are specifically reversed by neutralizing anti-LC1 antisera that would be unlikely to penetrate cells but could readily sequester LC1 at pericellular sites (7-11). Finally, human recombinant LC1 (hu-r-LC11-346) and a stable N-terminal LC1 fragment (LC11-188) mimic the inhibitory actions of glucocorticoids on the pharmacologi-
strated an excellent correlation between the presence of the cell surface binding protein and the capacity of an anti-LC1 monoclonal antibody to abrogate the inhibitory actions of dexamethasone (10 nM) on the release of ACTH initiated in vitro by CRH-41 (1 nM). Morphological analysis of cells harvested by FAC sorting showed that 1) somatotrophs, corticotrophs, lactotrophs, thyrotrophs, and gonadotrophs were all included in the population expressing LC1 binding sites; and 2) the LC1-binding sites assume a punctate distribution across the cell surface. These data show that anterior pituitary cells express high affinity surface LC1-binding protein(s); they thus provide further evidence for a specific membrane mechanism of action of LC1 in regulating the endocrine function of the anterior pituitary. (Endocrinology 138: 5341-5351, 1997) L IPOCORTIN 1 (LC1; also called annexin 1) is a 37-kDa member of the annexin superfamily of Ca 2ϩ -and phospholipid-binding proteins (1) (2) (3) . Since its initial identification in extracts of conditioned medium from glucocorticoid-stimulated peritoneal macrophages (4), LC1 has been shown to exhibit a wide range of glucocorticoid-like activities and has been widely advocated as a mediator of these steroids, particularly in immune/inflammatory cells (2, 3) and the neuroendocrine system (2, 5) . Our recent in vivo and in vitro studies have identified a significant role for LC1 in effecting the negative feedback action of the glucocorticoids in the hypothalamo-pituitary-adrenal axis at the levels of both the hypothalamus (5-7) and the anterior pituitary gland (5, 8) . Further studies have shown that LC1 also contributes to the less well documented inhibitory actions of the glucocorticoids on the release of PRL (9) , GH (10) , and TSH (11) . LC1 is expressed in abundance in the anterior pituitary gland where, as in several peripheral cell types (12, 13) , both its synthesis and subcellular distribution are under glucocorticoid control (8, 14) . Exposure of anterior pituitary tissue to glucocorticoids in vivo or in vitro thus increases the cellular turnover of LC1 causing 1) rapid exportation of the protein from intracellular stores to the outer surface of the cell membrane where it is retained by a Ca 2ϩ -dependent mechanism and 2) de novo synthesis of the protein to replenish the depleted tissue stores (15, 16) . Several lines of evidence from our functional studies suggest that the prompt exportation of LC1 from cells is critical because it enables the protein to gain access to cell surface binding sites and thereby to exert its biological actions. Firstly, on a temporal basis, exportation of the protein parallels manifestation of the steroid-induced inhibition of ACTH release (8) . Secondly, processes that inhibit the cellular exportation of LC1 (protein synthesis inhibitors and LC1 antisense oligonucleotides) also abolish the inhibitory actions of glucocorticoids on the secretion of ACTH, GH, PRL, and TSH in vitro (8 -10, 16) . Thirdly, the regulatory actions of the steroids on pituitary hormone release in vivo and in vitro are specifically reversed by neutralizing anti-LC1 antisera that would be unlikely to penetrate cells but could readily sequester LC1 at pericellular sites (7) (8) (9) (10) (11) . Finally, human recombinant LC1 (hu-r-LC11-346) and a stable N-terminal LC1 fragment (LC11-188) mimic the inhibitory actions of glucocorticoids on the pharmacologi-cally evoked release of ACTH, GH, PRL, and TSH from pituitary tissue in vitro, but would be not expected to traverse cell membranes within the prompt time frame of response (8 -11) . Our attempts to detect the putative cell surface LC1-binding sites in the pituitary gland and other tissues by conventional ligand-binding techniques have not been successful, largely because in our hands LC1 appears to unfold and, hence, to lose its bioactivity when radiolabeled. By contrast, fluorescence-activated cell (FAC) analysis has proved valuable in this regard, leading to the identification of cell surface LC1-binding sites on human and murine peripheral blood leukocytes (17, 18) and in various cell lines, including the rat pituitary GH 3 line (19) . Accordingly, in the present study we have used FAC analysis/sorting together with fluorescence and electron microscopy to detect, characterize, and localize LC1-binding sites on the surface of rat anterior pituitary cells. For comparison, we also performed a small number of experiments in which we examined LC1 binding to rat peripheral blood leukocytes.
Materials and Methods Animals
Adult male CFY rats (derived from the Sprague-Dawley strain) bred from a closed colony in-house at Charing Cross and Westminster Medical School were used. They were housed postweaning in groups of five per cage in a quiet room with controlled lighting (lights on, 0800 -2000 h) in which the temperature was maintained at 21-23 C. Food and water were available ad libitum. All experiments were started between 0800 -0900 h to avoid changes associated with the circadian rhythm.
Preparation of dispersed anterior pituitary cells
Suspensions of dissociated anterior pituitary cells were prepared according to established protocols (16, 20) . Briefly, the cells of anterior pituitary glands removed postmortem from 24 rats were dissociated with collagenase (0.2%, wt/vol) and deoxyribonuclease (0.05%, wt/vol; both from Sigma Chemical Co., Poole, UK) in buffer A [Earle's balanced salts solution (EBSS) enriched with BSA (0.4%, wt/vol; Sigma Chemical Co., St. Louis, MO) and Na 2 HCO 3 (28.5 mm)]; the resulting cell suspension was centrifuged twice through a solution of 4% BSA (200 ϫ g, 10 min) to remove small debris and erythrocytes and filtered through a 20-m nylon mesh to remove any remaining tissue clumps. In some experiments (Fig. 2 , B and C, and Fig. 4 , A-D), the cells were incubated (37 C) for an additional 10 min with trypsin (Sigma Chemical Co., St. Louis, MO; 0.05%, wt/vol, in buffer A); the protease action was halted by adding a 10-fold volume of EBSS containing BSA (2%), after which the cells were washed three times in buffer A and finally resuspended in buffer A. Samples of collagenase-or collagenase/trypsin-dispersed cells were examined by light microscopy to verify the effectiveness of the dispersion (Ͼ80%) and counted using a hemocytometer. The viability of the cells (normally Ͼ95%) was assessed by the trypan blue exclusion test. Additional samples of the cells were retained for examination at the electron microscope level.
Secretion of ACTH in vitro by enzymatically dispersed pituitary cells
Enzymatically dispersed cells were diluted in medium [EBSS enriched with aprotinin (1%; Bayer, Newbury, UK), pH 7.4] to a concentration of 3-5 ϫ 10 5 cells/ml and incubated under the conditions previously described (16) for 2 h. They were resuspended either in medium alone (controls) or in medium containing a submaximal concentration of synthetic rat CRH (CRH-41; 1 nm) and incubated in 0.6-ml aliquots for an additional 60 min. The cells were then centrifuged (600 ϫ g, 10 min, 4 C), and the supernatant fluid was collected and stored at Ϫ20 C for later measurement of immunoreactive ACTH (ir-ACTH). Where appropriate, an anti-LC1 monoclonal antibody [anti-LC1 mAb raised against bovine lung annexin 1; Zymed (San Francisco, CA) clone Z013; diluted 1:15,000] (8) or an isotype-matched (IgG1) control mAb (antispectrin ␣ and ␤ mAb; Sigma Chemical Co., St. Louis, MO; diluted 1:15,000) was added to the final incubation medium (8, 20) ; if required, dexamethasone (10 nm) was included in the medium during both the preincubation and the final incubation periods. The specificity of the anti-LC1 mAb was previously described (8) ; when used for Western blot analysis, it reveals a single band of LC1 immunoreactivity in pituitary extracts with a molecular mass (37 kDa) corresponding to that of the LC1 standard preparation.
Detection of cell surface LC1-binding sites by FAC analysis
Peripheral blood leukocytes. Preliminary experiments investigated binding of LC1 to rat peripheral blood leukocytes by methods analogous to those reported previously for detection of murine and human leukocyte LC1-binding sites (17, 18) . Cellular fractions were isolated from trunk blood collected immediately after decapitation and diluted with sodium citrate (0.36%, wt/vol, in distilled water; 1-6 ml blood), using a single step Ficoll-Hypaque M-85 gradient (Pharmacia, Uppsala, Sweden; Winthrop Pharmaceuticals, Rennsaler, NY) (21) . The leukocyte fractions were pooled, washed twice in PBS (10 ml, 400 ϫ g, 10 min, 22 C), resuspended in buffer A (5 ml), and examined at the light microscope level with the aid of a hemocytometer; a population comprising lymphocytes (70%), monocytes (15%), and polymorphonuclear neutrophils (PMNs; 15%) was observed. The cells were then washed with PBS containing EDTA (1 mm), which chelates Ca 2ϩ and thereby removes any LC1 that may be associated with the cell membrane (18, 22) , and diluted in buffer A to a concentration of 2.5-5 ϫ 10 6 cells/ml. Aliquots (20 l) of the cell suspension were placed in the wells of a 96-well microtiter plate (Falcon, Becton Dickinson, Oxford, UK) and incubated in the presence of graded concentrations of hu-r-LC1 (0.5-500 nm) for 60 min at 4 C. The cells were washed in PBS (200 l) containing BSA (0.2%, wt/vol) and CaCl 2 (1.3 mm; PBC) to remove any free hu-r-LC1. Hu-r-LC1 bound to the cell surface was detected by a double antibody method. Briefly, the cells were incubated in buffer A at 4 C for 60 min in the absence (controls) or the presence of a specific antihuman LC1 mAb (coded anti-LC1 mAb 1B; 20 g/ml) together with rat IgG (5 mg/ml; Sigma Chemical Co., St. Louis, MO) to block nonspecific antibody binding. The cells were then washed three times with cold PBC (200 l), incubated at 4 C for an additional 30 min with goat antimouse IgG-fluorescein isothiocyanate (FITC) conjugate (diluted 1:100; Caltag, San Francisco, CA), and washed in cold PBC; they were then resuspended in PBC (200 l), fixed in an equal volume of paraformaldehyde (2%, wt/vol, in PBS) and stored (4 C) for FAC analysis (see below), which was performed within 4 days.
Anterior pituitary cells.
Pituitary cell suspensions (0.6 ml; 3-5 ϫ 10 5 cells/ml) were prepared and preincubated for 2 h as described above. The cells were then washed twice with PBS (2 ml; pH 7.4) and once with PBS containing EDTA (1 mm) and resuspended in buffer A (1-2 ϫ 10 7 cells/ml). Aliquots (20 l) of the cell suspension were transferred to the wells of a flat-bottomed 96-well microtiter plate and incubated with hu-r-LC1 (0.5-500 nm) at 4 C (or 37 C for experiments shown in Fig. 3D ) for 1 h. LC1 bound to the cell surface was determined by FAC analysis using the protocol described above for leukocytes. As an additional control, an equal concentration of an isotype-matched (IgG2a) control mAb (antitropomyosin; 20 g/ml; Sigma Chemical Co.) was substituted for anti-LC1 mAb. The specificity of the LC1 binding was (Fig. 4, B-D) , pituitary cells separated by collagenase-trypsin treatment were cultured in the presence or absence of inhibitors of RNA (actinomycin D, 0.1 g/ml) or protein [cycloheximide (0.5 g/ml) and puromycin (2 g/ ml)] synthesis for 24 h before incubation with graded concentrations of hu-r-LC1 (0.5-500 nm); the concentrations of RNA/protein synthesis inhibitors were selected on the basis of previous experiments in which de novo protein synthesis in pituitary tissue in vitro was measured directly (9) .
FAC analysis and sorting. Surface fluorescence on both the anterior pituitary cells and the leukocytes was quantified by FAC analysis using a FACScan analyzer (Becton Dickinson) with air-cooled 100-mW argon laser (488 nm) detection and a Consort 32 computer running Lysis II software. A total of 10,000 cells were counted per sample; particles too large to be single cells, as determined by forward light scatter, were gated out electronically. Lymphocytes, neutrophils, and monocytes were differentiated within the leukocyte population by their forward and side light-scattering characteristics (17, 18) ; in contrast, no clear subpopulations of pituitary cells could be discerned in this way. The number of LC1-binding sites per cell was estimated by comparison of the median fluorescence intensity in the FL1 channel with reference to microbeads labeled with FITC standards (Flow Cytometry Standard Corp., Atlanta, GA) according to the method of Le Bouteiller et al. (23) . Briefly, the median fluorescence intensity of each sample is converted to mean FITC molecules bound per cell by comparison with a standard measure, i.e. the binding of standard amounts of FITC to microbeads. The resultant value is then divided by the fluorescence/protein ratio of the FITC-conjugated second antibody to yield the number of antibody binding sites per cell. Assuming a monovalent interaction of LC1 with the primary antibody, the number of binding sites per cell is divided by the Avogadro constant to calculate the number of moles bound. Apparent dissociation constants (K d ) for LC1 binding were determined by a method approximating Scatchard analysis for fluorescence-activated cell analysis (FAC), where free ligand is estimated by subtraction of moles bound from total moles added (17, 18) . Scatchard plots of the moles of LC1 bound divided by the estimate of the free ligand concentration against moles of LC1 bound were plotted, and the apparent dissociation constant (K d ) and binding capacity (B max ) values were calculated from the gradient and x-axis intercepts, respectively, by use of Kaleidograph software (Synergy Software, Philadelphia, PA).
In some experiments, the fluorescence-labeled cells (i.e. those expressing cell surface LC1-binding sites) were separated by FAC sorting (FACStar Plus, Becton Dickinson). The positive cells were then characterized on a morphological basis and by immunogold cytochemistry at the electron microscope level (see below). Cell surface fluorescence was also visualized by conventional fluorescence (BH2-RFL reflected fluorescence microscope, Olympus, Lake Purchase, NY) and confocal (MRC-500 laser scanning device, Bio-Rad, Richmond, CA) microscopy after smearing the labeled cells onto gelatin-coated slides.
Electron microscopy
Anterior pituitary cells (freshly dispersed and after separation by FAC sorting) were prepared for electron microscopy using standard methods. Briefly, the cells were fixed with glutaraldehyde (Sigma Chemical Co., St. Louis, MO; 2.5%, vol/vol, in PBS), postfixed in osmium tetroxide (1%, wt/vol, in 0.1 m phosphate buffer), stained with uranyl acetate (2%, wt/vol, in distilled water), dehydrated through a series of increasingly concentrated ethanol (70 -100%), and embedded in Spurr's resin (Agar Scientific, Stansted, UK). Ultrathin sections (50 -80 nm) were viewed with a JEOL transmission microscope (JEM-1010, JEOL, Peabody, MA). Cells in sections taken systematically from different depths of the embedded cell pellet were identified on the basis of their secretory granule populations (shape, electron density, size, and distribution), organelle structures, nucleus size, and chromatin characteristics (24) and by immunogold labeling (25) . Cells from individual samples were always identified and counted on four to eight randomized grids in a systematic manner.
Determination of ACTH
ACTH was determined in duplicate by RIA (16, 26) using a primary antibody of defined specificity raised in rabbits against human ACTH-(1-39) (National Hormone and Pituitary Program, Bethesda, MD), synthetic human ACTH-(1-39) as a reference preparation (National Institute for Biological Standards and Control, South Mimms, UK), and [ 125 I]ACTH-(1-39) as the tracer. The assay sensitivity was 10 pg/ml, and the inter-and intraassay coefficients of variation were 10.0% and 5.2%, respectively. Dilution curves of the test samples were parallel those of the standard ACTH preparation.
Drugs
The following were used: dexamethasone sodium sulfate (David Bull Laboratories, Slough, UK); CRH-41 (Bachem, Torrance, CA); anti-LC1 mAb (for in vitro immunoneutralization studies, Zymed, clone Z013); hu-r-LC1 and anti-LC1 mAb 1B (for FAC analysis/sorting, both from Biogen Research Corp., Cambridge, MA); FITC-conjugated goat antimouse IgG antibody and FITC-conjugated goat antirabbit IgG antibody (both from Caltag); human placental annexin 5 (gift from Dr. F. RussoMarie, Paris, France); GH (National Hormone and Pituitary Program, Bethesda, MD); and actinomycin D, puromycin, cycloheximide, antispectrin ␣ and ␤ mAb, and antitropomyosin mAb (all from Sigma Chemical Co., St. Louis, MO). The drugs were dissolved and/or diluted as appropriate in incubation medium immediately before use.
Statistical analysis
Preliminary analysis by the Shapiro and Wilkes test showed that the data were normally distributed. Subsequent analysis was performed by ANOVA with post-hoc comparisons by Duncan's multiple range test. Differences were considered significant if P Ͻ 0.05. Statistical analyses were made within experiments only. Each of the studies shown was repeated at least three times (for specific details, see legends), and in all instances a similar profile of data were seen. Figure 1A demonstrates the binding of hu-r-LC1 to rat peripheral blood leukocytes as detected by anti-LC1 mAb 1B with an antimouse IgG FITC-conjugated second antibody and quantified by computerized FAC analysis. Concentration-dependent binding of hu-r-LC1 (0.5-500 nm) to PMNs and monocytes was observed, with saturation at 50 nm, giving a total of 33,000 Ϯ 4,000 binding sites/cell (mean Ϯ sem) for the monocytes and 27,000 Ϯ 4,000 for the PMNs (n ϭ 4). Approximately 95% monocytes and PMNs displayed a fluorescence shift on LC1 binding. In contrast, the lymphocyte population did not bind hu-r-LC1. Scatchard analysis of the data (by the approximation for flow cytometry) yielded straight line plots, with K d and B max of 3 Ϯ 1 nm and 50 Ϯ 13 pm, respectively, for PMNs and 4 Ϯ 2 nm and 42 Ϯ 18 pm for monocytes (n ϭ 3; Fig. 1B) . Removal of Ca 2ϩ from the medium completely prevented the binding of hu-r-LC1 (2.6 -260 nm; P Ͻ 0.01, Ca 2ϩ free vs. control; n ϭ 4; Fig. 1C) . Similarly, the binding of hu-r-LC1 (2.6 -260 nm) was almost completely abolished by pretreatment of the monocytes with trypsin (0.05%; 10 min; 37 C; P Ͻ 0.01, trypsin-treated vs. control; n ϭ 4; Fig. 1D ).
Results

Detection of LC1-binding sites on peripheral blood leukocytes
Secretion of ACTH by dispersed anterior pituitary cells
Preliminary experiments confirmed that collagenase-dispersed anterior pituitary cells respond to CRH-41 (0.1-1000 nm) with concentration-dependent increases in the release of ir-ACTH that are readily inhibited by preincubation of the cells with dexamethasone (1-100 nm; P Ͻ 0.01; data not shown). On the basis of these experiments, a concentration of CRH-41 (1 nm) that produced a response approximately 80% of the maximal response was selected for further study together with a concentration of dexamethasone (10 nm) that blocked the secretory response to CRH-41 (1 nm) by approximately 85%. Examination of the cells at the electron microscope level revealed that the ultrastructure was well main-tained after the dispersion process and that all of the main secretory cell types were present in the suspension in proportions similar to those observed in vivo (Table 1) ; a small proportion of nonsecretory cells (ϳ5%) was also observed, but the bulk of the folliculostellate and macrophage populations was lost during the dispersion process. Figure 2 illustrates the effects of an anti-LC1 mAb (diluted 1:15,000) on the ability of dexamethasone (10 nm) to suppress CRH-41-stimulated release of ir-ACTH in vitro from anterior pituitary cells preincubated either for 2 h after dispersion with collagenase ( Fig. 2A) or collagenase/trypsin (Fig. 2B) or for 24 h after dispersion with collagenase/trypsin (Fig. 2C) . In the presence of the control antibody (antispectrin ␣ and ␤ mAb, diluted 1:15,000), all three cell preparations responded to CRH-41 (1 nm) with significant increases in ir-ACTH release; however, the responses of cells separated with collagenase/trypsin and preincubated for only 2 h before stimulation were generally smaller and showed a greater variance ( Fig. 2B ; P Ͻ 0.05) than those of either collagenasedispersed cells ( Fig. 3A ; P Ͻ 0.01) or cells allowed to recover for 24 h in culture after separation with collagenase/trypsin ( Fig. 2C ; P Ͻ 0.01). Nonetheless, the responses to CRH-41 in the three preparations were blocked by dexamethasone (P Ͻ 0.05), which alone did not influence the spontaneous release of the pituitary hormone. In the absence of dexamethasone, inclusion of anti-LC1 mAb in the medium had no significant effect (vs. the control mAb) on either the basal release of ir-ACTH or the secretory responses to CRH-41, nor did the antibody influence basal peptide release in the presence of dexamethasone (Fig. 2, A-C) . However, in the collagenasedispersed rat anterior pituitary cells ( Fig. 2A) , anti-LC1 mAb effectively reversed the inhibitory effects of dexamethasone on the increases in ir-ACTH evoked by CRH-41. By contrast, anti-LC1 mAb failed to influence the modest inhibitory actions of dexamethasone on CRH-41-stimulated ir-ACTH release in cells preincubated for 2 h after dispersion with collagenase/trypsin (Fig. 2B) . However, when the collagenase/ trypsin-dispersed cells were permitted to recover in culture for 24 h, responsivity to the antibody was reinstated; thus, treatment of these cells with anti-LC1 mAb fully reversed the inhibitory actions of dexamethasone on CRH-41-stimulated ir-ACTH release (Fig. 2C) . was observed with saturation at 250 nm, giving a total of 139,000 Ϯ 15,000 binding sites/cell (Fig. 3A) . By contrast, when a control mAb (antitropomyosin) was substituted for anti-LC1 mAb, no change in fluorescence above the background level was observed (data not shown). Scatchard analysis of the data (using the approximation for flow cytometry) yielded a straight line plot, an apparent K d of 14 Ϯ 3 nm, and a B max of 32 Ϯ 13 pm (Fig. 3B) . Removal of Ca 2ϩ from buffer A during the incubation with hu-r-LC1 (0.5-500 nm) and from PBC during the subsequent washes completely abolished the ability of hu-r-LC1 to bind to the cells (P Ͻ 0.01, Ca 2ϩ vs. Ca 2ϩ -free at all concentrations of hu-r-LC1; Fig. 3C ). Performing the incubation with hu-r-LC1 (0.5-500 nm) at 37 C also reduced LC1 binding significantly (P Ͻ 0.01 vs. binding at 4 C; Fig. 3D ). Figure 4 illustrates the effects of exposing collagenasedispersed anterior pituitary cells to trypsin (0.05%; 10 min at 37 C) on the expression of cell surface hu-r-LC1-binding sites. The binding of hu-r-LC1 (1-500 nm) to the cells was promptly abolished (P Ͻ 0.01; n ϭ 3) by trypsin treatment, but was fully reinstated when the trypsinized cells were allowed to recover for 24 h in culture before study (binding sites per cell at saturation: trypsin plus 24 h in culture, 139,000 Ϯ 15,000; nontrypsinized cells, 132,000 Ϯ 17,000; K d : trypsin plus 24 h in culture, 15 Ϯ 3 nm; vehicle, 14 Ϯ 2 nm; n ϭ 3; Fig. 4A ). Regeneration of the binding sites was prevented by inclusion in the medium of the protein synthesis inhibitors cycloheximide (0.5 g/ml; Fig. 4C ) or puromycin (2 g/ml; Fig. 4D ), but not by the RNA synthesis inhibitor actinomycin D (0.1 g/ml; Fig. 4B ).
Detection of LC1-binding sites on anterior pituitary cells
The binding of hu-r-LC1 (2 nm) to anterior pituitary cells was unaffected by the inclusion of CRH-41 (20 -200 nm) in the medium (Fig. 5A) ; similarly, hu-r-LC1 (20 nm) binding was unaffected by GH (100 -200 nm; Fig. 5B) . Moreover, when the pituitary cells were mixed with leukocytes before incubation   FIG. 4 . A, The effects of trypsin (10 min; 0.05%, wt/vol) with and without a subsequent 24-h culture period, on the binding of hu-r-LC1 (0.5-500 nM) to collagenase-dispersed rat anterior pituitary cells. F, Controls (i.e. collagenase dispersed); å, trypsin treatment without subsequent culture; E, trypsin treatment and 24-h culture. B-D show the effects of inclusion in the culture medium of the RNA synthesis inhibitor actinomycin D (B; 0.1 g/ml) and the protein synthesis inhibitors cycloheximide (C; 0.5 g/ml) and puromycin (D; 2 g/ml) on the ability of collagenase/trypsin-dispersed cells maintained in culture for 24 h to regenerate hu-r-LC1 binding sites. with hu-r LC1 and FAC analysis/sorting, the lymphocytes were confined to the population negative for LC1-binding sites, whereas the monocytes and neutrophils were selectively contained within the population displaying fluorescence for LC1 binding (Table 2 ). However, annexin 5 (100 and 200 nm) blocked the binding of hu-r-LC1 (20 nm) to the cells by approximately 60% and 95%, respectively, suggesting competition for a single site (Fig. 5C) .
Distribution of LC1-binding sites in the pituitary gland and on peripheral blood leukocytes
Examination by confocal and fluorescence microscopy of pituitary and blood cells treated sequentially with hu-r-LC1 (100 nm), anti-LC1 mAb 1B, and the FITC-conjugated second antibody demonstrated clear LC1 binding to the outer surface of the cells; the binding was nonuniform, appearing as punctate clusters of fluorescence that varied in intensity (Fig.  6 , A-D; n ϭ 8). Visualization of pituitary cells separated by FAC sorting (on the basis of hu-r-LC1 binding) at the electron microscope level confirmed that the ultrastructural integrity of the cells was well maintained during passage through the cytometer (Fig. 7) . It also showed that the proportion of pituitary cells expressing hu-r-LC1-binding sites represents approximately 80% of the cell population tested. All of the main secretory (i.e. endocrine) cells were identified on the basis of morphological criteria in this fraction (i.e. somatotrophs, gonadotrophs, corticotrophs, thyrotrophs, and lactotrophs; Fig. 7 ) in proportions comparable to those observed in normal pituitary tissue or in collagenase-dispersed cells before sorting (Table 1) . Identification and quantification of cell types on the basis of morphology correlated well with the data obtained when identification was assisted by immunogold labeling for the respective stored pituitary peptides. Further examination of cells showing strong fluorescence for hu-r-LC1 binding by conventional confocal microscopy confirmed that this population comprised cells of differing sizes that appeared intact. Cells not expressing hu-r-LC1-binding sites separated from a mixture of anterior pituitary cells were found to comprise mainly lymphocytes, but also somatotrophs and gonadotrophs (Table 2) .
Discussion
Substantial evidence supports the view that LC1 is an important mediator of the regulatory actions of the glucocorticoids in the neuroendocrine system (reviewed in Refs. 2 and 5), particularly at the level of the anterior pituitary gland (8 -11) . The mechanism(s) by which LC1 suppresses pituitary hormone release is not known, although our previous studies (reviewed in the introduction) strongly favor actions via a cell surface "receptor." The present study demonstrates for the first time the presence of high affinity LC1-binding sites on the surface of multiple anterior pituitary cell types and, thus, adds further support to this view; it also provides novel evidence that LC1-binding sites are expressed on specific populations of rat leukocytes.
FAC analysis has been used effectively to detect and characterize high affinity LC1-binding sites on the surface of human and murine peripheral blood leukocytes, and indeed, these sites are deemed necessary for the biological actions of the protein (3, 17, 18, 27) . In line with these findings, we report for the first time the presence of similar high affinity, saturable, LC1-binding sites on the surface of rat peripheral blood monocytes and PMNs, but not lymphocytes. In addition, we have revealed by fluorescence and confocal microscopy that the distribution of the binding sites on the cell surface is punctate and variable between cells; this pattern is consistent with the widespread phenomenon of ligand-induced receptor clustering, a process that may be essential for internalization (28) . There was no significant difference between the monocytes and PMNs with regard to either the estimated K d or the B max ; moreover, these values closely resemble those reported for LC1 binding to human and murine leukocytes (17, 18, 27) . It is evident from our study that LC1 binding is Ca 2ϩ dependent, which supports the known Ca 2ϩ requirements for LC1 biological activity (1). The fact that LC1 does not bind to lymphocytes argues against the possibility that the protein is merely binding nonspecifically to surface membrane phospholipids as does the K d , which is indicative of a putative receptor. Indeed, our finding that the LC1 B max of the cells is destroyed by trypsin suggests that the binding site(s) is proteinaceous in nature; similar conclusions have been drawn from a recent study on human monocytes in which LC1 binding was ablated by pretreatment of the cells with proteases (18, 29) . In accord with these findings, two LC1-binding proteins (with molecular masses of 15 and 18 kDa) have been identified on the surface of human monocytes (18), but their exact nature is not yet known.
Although flow cytometry is used routinely to type immune cells on the basis of specific cell surface marker expression, little work has been published on the use of this technology to detect and quantify surface antigens or receptors on anterior pituitary cells. Inevitably, with a solid tissue such as the pituitary gland, there are methodological problems in balancing the need to preserve surface proteins with the conflicting requirement for FAC analysis of a preparation of single cells, the production of which entails digestion of the connective tissue between the cells with proteases that are Cells were identified by electron microscopy, and the data are expressed as a percentage of the total cells counted. Values represent the mean percentage of a cell type Ϯ SEM (n ϭ 3 sorts).
themselves likely to damage the surface proteins. We thus investigated three methods of anterior pituitary cell preparation (viz. collagenase, collagenase/trypsin, and collagenase/trypsin plus 24 h in culture) and complemented our study of the capacity of the dispersed cells to bind LC1 with measures of the morphological and functional integrity of the cells. Our data indicate that both the ultrastructure and the viability of the pituitary cells were well maintained regardless of the method of separation. Moreover, the three preparations each responded readily to CRH-41 in vitro with significant rises in ir-ACTH release that were readily attenuated by preincubation of the cells with dexamethasone; however, the responses of the collagenase/trypsin-treated cells to both CRH-41 and dexamethasone (Fig. 2B) were generally smaller and more variable than those of the other groups (Fig. 2, A and C) . High affinity, saturable LC1-binding sites were readily detected by FAC analysis on the surface of approximately 80% of anterior pituitary cells separated by collagenase; in contrast, cells exposed to trypsin failed to bind hu-r-LC1, although their binding capacity was restored after 24 h in culture. There was an excellent correlation between the presence of the cell surface binding site and the capacity of our anti-LC1 antibody to quench the powerful inhibitory effects of dexamethasone on ir-ACTH release. Thus, in accord with our previous observations on pituitary segments (8), anti-LC1 mAb effectively suppressed the inhibitory actions of dexamethasone on CRH-41-stimulated ir-ACTH release from the collagenase-dispersed cells; the action of the antibody appeared to be specific, because an isotype-matched control antibody was ineffective in this regard. However, in cells in which the surface hu-r-LC1-binding sites were destroyed by trypsin, the LC1-neutralizing antibody was without effect. In contrast, when the trypsinized cells were maintained in culture for 24 h to reinstate LC1 binding, the ability of the antibody to quench the inhibitory actions of the steroid was restored. These data add further support to our hypothesis (2, 5, (7) (8) (9) (10) (11) ) that LC1 acts via membrane-bound proteins to suppress peptide release. The fact that cells subjected to collagenase/trypsin treatment still showed weak responses to dexamethasone despite their loss of sensitivity to anti-LC1 mAb is interesting and supports our premise (2, 5) that the steroid may exploit more than one mechanism of action in a given target cell.
Our data also show clearly that the binding of hu-r-LC1 to collagenase-dispersed pituitary cells is concentration, temperature, and Ca 2ϩ dependent and that the binding sites assume a punctate pattern of distribution across the cell surface that appeared to vary between cells. The overt reduction in B max evident at 37 C vs. that at 4 C is difficult to explain, but may reflect more rapid internalization of the FIG. 6 . Distribution of hu-r-LC1-binding sites on the surface of collagenase-dispersed rat anterior pituitary cells (A and C) and rat peripheral blood leukocytes (B and D) visualized by low power fluorescence microscopy (A and B; magnification, ϫ300) and scanning laser confocal microscopy (C magnification, ϫ1000; D magnification, ϫ500); the binding sites were exposed by sequential incubation of the cells with hu-r-LC1 (100 nM), anti-LC1 mAb 1B, and an antimouse IgG FITC-conjugated second antibody. In all cases, the distribution of bound h-r-LC1 on the cell surface was punctate. No binding was detected in controls incubated with hu-r-LC1 (100 nM) and antimouse IgG FITC-conjugated second antibody (data not shown).
ligand-binding site complex. Two lines of evidence indicate that, as in leukocytes, LC1-binding sites on anterior pituitary cells are protein in nature. Firstly, the capacity of the pituitary cells to bind hu-r-LC1 is destroyed by trypsin; secondly, the subsequent regeneration of the binding sites in culture is prevented by the inclusion in the medium of the protein synthesis inhibitors cycloheximide and puromycin, although, surprisingly, not by the RNA synthesis inhibitor actinomycin D. These findings indicate that the reinstatement of the binding site in culture is dependent on the translation, but not the transcription, of new protein; they thus suggest that a readily translatable pool of RNA (primary transcript or mature messenger RNA) for the LC1-binding protein RNA exists within anterior pituitary cells.
The specificity of the binding measured was an important consideration. In all of our experiments, fluorescence in the absence of ligand and/or primary antibody was minimal; the specificity of the primary antibody was further assured by the fact that our isotype-matched control antibody (antitropomyosin) was repeatedly inert. Three additional questions were addressed to gain some insight into the specificity of hu-r-LC1 binding to collagenase-dispersed anterior pituitary cells; namely, was the binding of profile hu-r-LC1 altered by the addition to the cell suspension of 1) a cell known not to express LC1 binding sites (i.e. lymphocytes), 2) high physiological concentrations of other hormones, and 3) other annexins? Spiking of the pituitary cell suspension with leukocytes had no discernible effect on the binding profile; moreover, morphological examination of samples harvested by FAC sorting confirmed that the lymphocytes were confined to the population negative for LC1 binding. The binding of hu-r-LC1 to the pituitary cells was also unaffected by CRH-41 and GH, which suggests that the interaction of LC1 with the cell membranes was not via a nonspecific protein association. An effect of CRH-41 might have been expected, as the N-terminal of LC1 exhibits some degree of sequence homology with members of the CRH peptide family, notably sauvagine (30) . Our finding that annexin 5 causes an apparent concentration-dependent inhibition of hu-r-LC1 binding to anterior pituitary cells raises the possibility that annexin family members may bind to a common site on the cell membrane. This view, however, is not supported by our recent experiments showing that hu-r-LC1 does not affect the binding of annexin 5 to pituitary cells. As annexins readily form multimers (31, 32) , one possible explanation of our data is that hu-r-LC1 combined with annexin 5 in solution to form a heteromultimer in which the epitope required for association of hu-r-LC1 either with its cell surface binding site or with the antibody probe (i.e. anti-LC1 mAb 1B) was masked.
FAC sorting permitted ready separation of the 80% of collagenase-dispersed anterior pituitary cells that displayed fluorescence for hu-r-LC1-binding sites. Identification of the cells harvested on the basis of morphological criteria at the electron microscope level indicated that all principal secretory (i.e. endocrine) cells emerged within this fraction, with no obvious enrichment of any particular secretory cell type; thus, somatotrophs, lactotrophs, corticotrophs, gonadotrophs, and thyrotrophs were all shown to express hu-r-LC1-binding sites. Parallel studies in which the pituitary cells were identified and quantified on the basis of immunogold labeling of the respective stored pituitary peptides led to similar conclusions. Unfortunately, the number of cells contained within the population not expressing LC1-binding sites was not sufficient for quantitative evaluation. However, in experiments in which the pituitary cells were mixed with leukocytes before FAC analysis/sorting, the population negative for LC1 binding was found to comprise not only the predicted abundance of lymphocytes, but also a surprisingly high proportion of somatotrophs and gonadotrophs. The reason why some cells of one secretory type should exhibit differences in hu-r-LC1 B max is unclear. It is possible that some cells are more prone to damage by protease treatment, but the ultrastructural morphology of the pituitary cells not expressing LC1-binding sites appeared intact. A more plausible explanation is that cells negative for LC1 binding are either at a different stage of a particular cycle (22) , or they belong to specific subgroups of the principal pituitary cell types that may be identified more readily on a chemical, rather than a morphological, basis.
An important question emerges as to whether the LC1-binding sites expressed on the pituitary cells are identical with those observed on leukocytes. There were no obvious differences between the two populations with regard to the LC1 B max ; moreover in both cases, LC1 binding was Ca This may reflect the relatively large surface area of the cells (vs. leukocytes); alternatively, it may be explained by a low affinity, high capacity site. Unfortunately, direct statistical comparisons of the measures of affinity and capacity were not possible, as parallel measurements of LC1 binding to leukocytes and anterior pituitary cells were not made in a sufficient number of experiments.
In conclusion, this study describes for the first time the presence of saturable, high affinity binding sites for hu-r-LC1 on the surface of multiple anterior pituitary cell types. These findings accord with data from our functional studies that have identified a role for LC1 in the regulation of secretion of several pituitary hormones, and they thus lend further support to our hypothesis that the actions of this protein are effected via cell surface, membrane-bound, binding sites. It remains to be determined whether these sites are true receptors, but both their high affinity and their punctate distribution accord with this view. As LC1 is expressed mainly by the agranular folliculostellate cells in the adenohypophysis, but also by the endocrine cells in the adenohypophysis (34), it is not yet clear whether LC1 binds to and acts on the cells from which it is released (i.e. as an autocrine agent) or whether it modulates the activity of adjacent cells (i.e. as a paracrine agent). Our finding that anti-LC1 mAb ablates the inhibitory actions of dexamethasone on ACTH release from collagenase-dispersed anterior pituitary cells in vitro, as it does in preparations in which the three-dimensional structure of the tissue is retained (8) , suggests that the actions of the protein are not dependent on cell-cell contacts. Nonetheless, we cannot exclude the possibility that there may be a requirement for cell juxtaposition in vivo for the LC1-producing cells to generate an effective concentration of the protein at the surface of the LC1-responsive cells. The folliculostellate cells would be well suited to participate in such mechanism because they are particularly rich in LC1, and their elongated processes make close contact with secretory endocrine cells. Further studies are now underway to identify the binding protein, the factors that modulate its expression, and the signal transduction pathways it uses in the pituitary gland to regulate hormone release.
